You are here

Article Text

Article menu
Download PDFPDF
Best Evidence Topic reports
BET 1: Lopinavir–ritonavir and COVID-19
  1. Daniel Dolan,
  2. Jack Ingham,
  3. Janos Baombe
  1. 1 Emergency Department, Manchester University NHS Foundation Trust, Manchester, UK
  1. Correspondence to Dr Charles Reynard, production.emj{at}bmjgroup.com

https://doi.org/10.1136/emermed-2020-210221.2

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Three-part question

    (In adult patients admitted to hospital with confirmed COVID-19) does (lopinavir–ritonavir) lead to (reduced mortality and/or reduced length of stay and/or reduced time to improvement)?

    Clinical scenario

    A 52-year-old man presented to the ED with a 9-day history of coryzal symptoms including sore throat and fever, after 5 days developed a dry cough and shortness of breath on exertion. His shortness of breath had become more severe over the last 24 hours, now breathless at rest and complaining of right-sided pleuritic chest pain. Chest X-ray and blood result findings were highly suspicious of COVID-19 …

    View Full Text